Inspra (Eplerenone)

Eplerenone works by selectively blocking mineralocorticoid (aldosterone) receptors in the distal nephron of the kidney. This inhibition prevents aldosterone‑driven sodium reabsorption and potassium excretion, leading to reduced fluid volume, lower blood pressure, and attenuation of harmful cardiac remodeling processes.

The dosage of Inspra is individualized by the prescribing clinician based on the patient’s medical condition, renal function, and potassium levels. The prescriber determines the appropriate starting dose and any subsequent adjustments, following clinical guidelines and patient monitoring.

Inspra is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus, but there are limited human data. It should be used during pregnancy only if the potential benefit justifies the potential risk. Caution is also advised while breastfeeding, and a healthcare professional should evaluate the risk‑benefit ratio.

To order Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details, and any necessary import documentation.

The primary alternative to eplerenone is spironolactone, another aldosterone antagonist. Eplerenone offers greater selectivity for mineralocorticoid receptors, resulting in fewer anti‑androgenic side effects such as gynecomastia. Both drugs lower blood pressure and improve heart‑failure outcomes, but eplerenone may be preferred when patients are sensitive to hormonal side effects.

Inspra tablets should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging to protect them from moisture and light. Do not store in a refrigerator or freezer, and keep out of reach of children.

Inspra is taken orally as a tablet, usually with or without food as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks associated with Inspra include severe hyperkalemia, which can be life‑threatening, and acute kidney injury, especially in patients with pre‑existing renal impairment. Regular monitoring of serum potassium and renal function is essential to detect these complications early.

Inspra is contraindicated in patients with known hypersensitivity to eplerenone, those with severe hyperkalemia (serum potassium >5.5 mmol/L), and individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²). Caution is also advised for patients taking other potassium‑raising agents.